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Purpose: The liver is one of the most common sites for metastatic solid tumors. If the liver is
the only site of metastatic disease, regional treatment options can offer the beneﬁt of high local
exposure with limited systemic toxicity, especially for patients without (further) systemic
treatment options. We report the results of our experience with isolated hepatic perfusion
(IHP) in patients with isolated liver metastases from a variety of primary tumors.
Patients and Methods: Nineteen patients with isolated unresectable liver metastases from a
variety of tumors (13 uveal melanomas, 2 neuroendocrine carcinomas, 2 gastrointestinal
stromal tumors, 1 hepatocellular carcinoma, and 1 high-grade sarcoma) were treated with a
60-min IHP using 200 mg melphalan. Patients were monitored for toxicity, response according
to response evaluation criteria in solid tumors (RECIST) criteria, and survival.
Results: One melanoma patient was not perfused due to insufﬁcient isolation of the liver.
There was no treatment-related mortality. Reversible grade 3 or 4 hepatoxicity occurred in 10
(56%) patients, while veno-occlusive disease occurred in 4 (22%) patients. Of the 12 uveal
melanoma patients who were perfused, 4 (33%) patients had a partial hepatic response, 6
(50%) patients had stable hepatic disease, and 2 (17%) patients were immediately progressive.
Median disease-free survival was 6.6 months with a median overall survival of 10.0 months.
Fifty percent of other primary tumors showed at least partial remission, including one com-
plete remission in a high-grade sarcoma patient.
Conclusion: IHP with melphalan shows activity in patients with liver metastases from a
variety of primary tumors, but other or additional drugs may improve therapeutic outcome.
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The liver is one of the most common sites for
metastatic disease and is involved in approximately
40% of adult patients with primary extrahepatic
malignant disease who undergo an autopsy. The most
common origin of hepatic metastasis conﬁned to the
liver is colorectal cancer. Neuroendocrine tumors and
uveal melanomas, although rare, are the second most
common origin of metastases conﬁned to the liver.
1
Gastrointestinal neuroendocrine tumors are predom-
inantly carcinoids (55%), consisting mainly of midgut
carcinoids (50–70%) which have the greatest potential
for metastasizing to the liver.
2,3 Uveal melanoma is
the most common primary intraocular tumor in
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1891adults, with an incidence of 5–7 per 1 million per year
in the Western population.
4 Up to nearly 50% of
patients will ultimately develop metastases, of which
more than 60% is conﬁned to the liver.
5,6 Other pri-
mary tumors that may initially metastasize exclusively
to the liver include gastrointestinal stromal tumors
(GIST) and even more rarely renal cell carcinoma,
Wilms’ tumor, and breast cancer. Although liver
metastases from primary tumors such as cancers of
the lung, breast, stomach, and cutaneous melanoma
may occur more frequently, dissemination usually
occurs simultaneously to other visceral locations.
If the metastases are conﬁned to the liver several
locoregional treatment options can be considered,
including partial hepatic resection, radiofrequency
ablation (RFA), administration of chemotherapy by
hepatic artery infusion (HAI), and isolated hepatic
perfusion (IHP) with high-dose chemotherapy.
Curative resection is possible in only a small fraction
of patients due to the number, location or size of the
metastases.
7,8 RFA is mainly suitable for patients
with a limited number of liver metastases that are not
located near any large vascular structures and less
than 5 cm in diameter.
9–11 Compared to HAI, IHP
offers the beneﬁts of high local drug exposure with
limited systemic toxicity.
12 Various studies have been
published on IHP for colorectal liver metastases,
13–15
but only a few studies have been reported on IHP for
liver metastases from other primary tumors.
16–20
In this study we present our experience with
19 patients with a variety of primary tumors other
than colorectal cancer, including uveal melanoma,
high-grade sarcoma, and GIST, who underwent IHP
at the Leiden University Medical Center.
PATIENTS AND METHODS
Patient Eligibility
Between May 1995 and May 2006, 19 patients with
liver metastases of uveal melanoma (13), GIST (2),
hepatocellular carcinoma (1), neuroendocrine carci-
noma (2), and high-grade sarcoma (1) were treated
with IHP with 200 mg melphalan according to a study
protocol approved by the local ethics committee.
Using the same melphalan dose, during the accrual
period, IHP was performed in 105 patients with
colorectal cancer hepatic metastases (13, 15 and van
Iersel, Annals of Oncology, in press 2008), indicating
feasibility and our experience with this procedure.
Informed consent was obtained from all patients. The
tumour response of eight uveal melanoma patients
has been previously reported.
21 Eligibility criteria in-
cluded a WHO performance status of 0 or 1, leukocyte
count ‡3.0 · 10
9/L, platelet count ‡100 · 10
9/L,
maximum serum creatinine level 135 lmol/L,
maximum bilirubin level 17 lmol/L, and minimum
albumin level 40 g/L. Exclusion criteria were age over
70 years, life expectancy of less than 4 months, more
than 60% hepatic replacement by tumor tissue as
estimated from the preoperative abdominal computed
tomography (CT) scan, coagulation disorders, and
evidence of extrahepatic metastatic disease. All
patients had a preoperative chest and abdominal
computer tomography (CT), full blood count, liver
function tests, and determination of lactate dehydro-
genase, albumin and creatinine, and electrolytes.
IHP Technique
Brieﬂy, the liver was mobilized from the diaphragm
through a transverse abdominal incision. The com-
mon hepatic artery (8-Fr 77008 one-piece pediatric
arterial cannula; Medtronic, Minneapolis, Minnesota,
USA) and the portal vein (12-Fr perfex perfusion
catheter CH12; B. Braun Medical, Oss, The Nether-
lands) were cannulated and connected to a heart–lung
machine which consisted of two independent roller
pumps (model 10-30-00; Cobe/Sto ¨ ckert, Munich,
Germany). For 14 patients both the hepatic arteryand
portal vein were used for inflow of melphalan in the
isolated circuit, because this technique was used in
our previously reported phase I
15 and II
13 study.
Although there is no established beneﬁt from drug
delivery by using the portal vein during our IHP
procedure oxygenated blood is perfused through the
portal vein and this may possibly prevent hypoxia-
induced damage to the liver. Moreover, by using our
technique, the MTD of melphalan is much higher
than reported by other groups who only used the
hepatic artery for drug delivery. For ﬁve patients we
used hepatic artery infusion at reduced ﬂow as
reported in a recent publication.
22 The inferior vena
cava (IVC) was cross-clamped above the hepatic veins
and cannulated proximal of the renal veins (Polystan
36 Fr, straight, A/S, Va ¨ rlo ¨ se, Denmark) to allow
undisturbed blood ﬂow from the hepatic veins
through the IVC towards the heart–lung machine. To
isolate the hepatic circuit, tourniquets were secured
around the hepatic artery, portal vein, and IVC.
For the extracorporeal venovenous bypass, the
right femoral vein (22-Fr cannula DIITF022L;
Edwards Lifesciences, Irvine, California, USA) and
the portal vein (17-Fr perfex perfusion catheter CH17;
B. Braun) (proximal to the tourniquet) were cannu-
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7326 perfusion cannula; Lifestream International,
The Woodlands, Texas, USA). The venovenous by-
pass was supported by a centrifugal pump (Medtronic
BIO-Medicus, Eden Prairie, Minnesota, USA) and
primed with 700 mL 0.9% saline. The perfusion
medium consisted of intrahepatically trapped blood
and 1250 mL Gelofusine
  (Vifor Medical, Sempach,
Switzerland) plus 2500 units heparin (Leo Pharma,
Breda, The Netherlands) to yield a ﬁnal volume of
approximately 2 liters. Throughout the 1-h perfusion
interval, the perfusate was kept at a temperature of
39.5 C by a heat exchanger and oxygenated using an
oxygenator (Cobe VPCML; Cobe Cardiovascular,
Arvada, Colorado, USA) except for the last three
patients who were oxygenated using a different oxy-
genator (Dideco D901, SORIN group Italia, Miran-
dola, Italy). After perfusion, the liver was ﬂushed for
approximately 10 min with 3 liters Gelofusine
 . All
cannula and clamps were removed, and the incisions
were closed. To prevent possible melphalan induced
cholecystitis, cholecystectomy was performed.
Melphalan
Melphalan 200mg (Alkeran
 , GlaxoSmithKline,
Zeist, The Netherlands) was ﬁrst dissolved in 40 mL
Wellcome Diluent [a 60/40 (v/v) mixture of proylene
glycol containing 5.2% (v/v) ethanol and 0.068 mol/l
sodium citrate], which was subsequently diluted with
60 mL sterile saline. Melphalan was administered as
a bolus in the isolated hepatic circuit
13,15 and in the
last ﬁve patients through 20-min infusion using an
infusion pump (Pilote Anesthesie; Fresenius, Brezins,
France) connected to the hepatic artery line of the
isolated hepatic circuit.
22
Leakage Detection
Leakage of perfusate into the systemic circuit was
monitored by adding 10 MBq
99mTc-pertechnetate to
the isolated circuit with subsequent measurement of
the level of radioactivity in both the systemic and
isolated circuit, as described previously.
23,24 If no
leakage was detected, melphalan was administered: If
leakage was calculated to exceed 10% during the
perfusion period, the procedure was stopped and the
liver was ﬂushed just before this level was reached.
Postoperative Care
All patients received a daily subcutaneous dose
of 480 lg granulocyte colony-stimulating factor
(G-CSF) (Filgrastim/Neupogen
 ; Amgen, Breda,
The Netherlands) starting the day after the operation
until the nadir in leukocyte count was reached and
the count had risen to more than 1.0 · 10
9/L. Pa-
tients were monitored in the intensive care unit for at
least 1 day after IHP. Liver and renal function tests
and full blood counts were carried out daily in the
ﬁrst week and henceforth as indicated by their
respective levels. Antibiotics in a combination of ce-
furoxim and metronidazol were given to all patients
for 5 days after IHP.
Toxicity
Systemic and regional toxicity data were collected
prospectively and graded retrospectively according to
the National Cancer Institute Common Toxicity
Criteria version 2.0. Hepatic toxicities were consid-
ered melphalan related if elevations in liver function
persisted beyond 7 days after perfusion, as previously
suggested.
25
Response Evaluation
Objective tumor response measurements were ob-
tained by follow-up CT scans of the liver and
remaining abdomen at 3-month intervals after treat-
ment and at 6-month intervals after 1 year. Addi-
tional imaging was performed if clinically indicated.
All Ct scans were revised using RECIST criteria to
determine response rates. For the response evaluation
criteria in solid tumors (RECIST) criteria lesions
were only considered measurable if ‡10 mm, com-
plete response was deﬁned as disappearance of all
known disease, partial response as a reduction in the
sum of maximal diameters of ‡30%, stable disease as
a reduction of \30% or an increase of \20% and
progressive disease as an increase of ‡20% or the
appearance of new intra- or extrahepatic lesions.
26
Disease-free survival was calculated from the date of
IHP until the date of local and/or systemic recurrence
or death from any cause.
Statistical Analysis
All data were analyzed with SPSS statistical soft-
ware (version 14.0. for Windows, SPSS, Chicago, IL,
USA). The analyses of time to progression and
survival were carried out by the Kaplan–Meier
method. If patients died before hepatic progression
had occurred, date of death was taken as date of
progression.
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Patient and Treatment Characteristics
Patient and tumor characteristics are listed in
Table 1. A total of 19 patients with unresectable liver
disease and no evidence of extrahepatic disease were
considered eligible for IHP. Thirteen patients pre-
sented with uveal melanoma as primary tumor, two
patients with a GIST, two patients with neuroendo-
crine carcinoma, one patient with hepatocellular
carcinoma (HCC), and one patient with high-grade
sarcoma. Sixteen patients presented with metachro-
nous liver metastases. The mean number of liver
metastases was 24 (range 1 to [100) with a mean
estimated hepatic replacement of 23% (range 5–
50%). Mean time from diagnosis of liver metastases
to IHP was 4.3 months (range 0.7–13.7 months).
Five patients received chemotherapy prior to IHP.
All 19 patients underwent IHP, but in 1 patient the
procedure failed due to failure to obtain suﬃcient
isolation of the liver and this patient was excluded
from further analyses. Treatment characteristics of
the remaining 18 patients are similar to our previous
experience with colorectal cancer patients and are
listed in Table 2.
13 Median operating time was
8 hours 7 min, with a median blood loss of 3.5 liters
(range 1–8 liters). Median hospital stay was 11 days
(range 7–25 days). Median follow-up was 74 months
(range 4–137 months).
Toxicity and Complications
Ten patients experienced grade 3 or 4 toxicity of
one or more liver enzymes 1 week after IHP, as
shown in Table 3. This hepatoxicity was transient
and only persisted in the four patients that developed
veno-occlusive disease (VOD). Major complications
occurred in ﬁve patients; as previously mentioned,
four patients developed signs of VOD and one other
patient experienced a lung embolism. Neutropenia
was rare and no neutropenic infections occurred.
Given the low leakage rate G-CSF, which was com-
mon practice since early development of this proce-
dure in phase I, is deemed unnecessary in future
patients. All patients left the hospital within 4 weeks.
Tumor Response, and Progression-Free and Overall
Survival
The patients with uveal melanoma and the patients
with liver metastases from other primary tumors were
analyzed separately. The details on tumor responses,
progression-free survival and overall survival details
of the six patients with primary tumors other than
uveal melanoma are given in Table 4. The high-grade
sarcoma patient had a complete response for
27.1 months while one neuroendocrine tumor patient
had a partial response for 33.4 months and was still
alive at the end of follow-up.
Of the 12 uveal melanoma patients, 4 (33%) pa-
tients had a partial hepatic response, 6 (50%) patients
had prolonged stable hepatic disease, and 2 (17%)
patients were immediately progressive. Progressive
disease occurred in all patients during follow-up. Six
(50%) patients had hepatic progression, three (25%)
had extrahepatic progression, and three (25%) were
both hepatic and extrahepatic progressive. Progres-
sion-free and overall survival curves for uveal mela-
noma patients are shown in Fig. 1. The median time
to hepatic progression was 8.2 months (range 1.7–
17.1 months), while median time to overall progres-
sion after IHP was 6.6 months (range 1.7–
17.1 months). All but one patient died during follow-
up. The median overall survival after IHP was
10 months (range 4.8–47.6 months), with median
TABLE 1. Patient and tumor characteristics
Characteristic n (%)
No. of patients 19
Sex
Male 6 (32)
Female 13 (68)
Primary tumor
Uveal melanoma 13
Neuroendocrine tumor 2
GIST 2
HCC 1
High-grade sarcoma 1
Median age in years (range) 51.4 (29–69)
Liver metastases
Synchronous 3 (15.8)
Metachronous 16 (84.2)
Mean hepatic replacement, % (range) 23.4 (5–50)
Median no. of metastases (range) 12 (1 to[100)
Median time of diagnoses of hepatic
metastases to IHP
2 (0.7–13.7)
TABLE 2. Treatment parameters
Parameter Mean±SD
Flow rate hepatic artery (mL/min) 290.4±100
Flow rate portal vein (mL/min) 230.8±97.3
Pressure hepatic artery (mm/Hg) 118.1±24.6
Pressure portal vein (mm/Hg) 36.5±9.3
Percentage leakage during perfusion 2.6±4.9
Blood loss (L) 3.9±2
Operative time (h) 8.9±1.3
Hospital stay (days) 12.7±4.8
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12.2 months (range 8.7–49.6 months).
DISCUSSION
This study shows that IHP with 200mg melphalan
shows activity in patients with liver metastases of
primary tumors other than colorectal cancer. Tran-
sient grade 3 or 4 hepatotoxicity was observed in 56%
of patients, similar to the results of previous stud-
ies.
19,27 The incidence of VOD (4/18) was relatively
high compared to the results in colorectal cancer
patients. VOD is thought to result from cumulative
exposure to chemotherapeutic agents, but only ﬁve
patients in this study received chemotherapy prior to
IHP and none of them developed VOD.
28 The pa-
tients with VOD showed similar characteristics as
compared to the patients without VOD, except for
the fact that the incidence of VOD was higher (2/5) in
the patients treated with hepatic artery infusion at
reduced ﬂow, a technique that was recently aban-
doned by us because of limited response rates and
hepatotoxicity. This leaves 3 VODs out of 13 patients
treated with melphalan through hepatic artery and
portal vein inﬂow, which is considered acceptable
toxicity. Of note, 5% underwent a major laparotomy,
but could not be perfused: this was due to extrahe-
patic disease that was not observed on CT scanning.
In order to reduce the incidence of unexpected
extrahepatic disease on laparotomy, optimal staging
with positron emission tomography (PET) scanning
is being introduced for future patients. Response
rates, disease-free and overall survival remain difﬁ-
cult to interpret due to small numbers and should be
evaluated in view of the lack of other treatment op-
tions in patients with the tumors that were included in
this study.
For the treatment of metastatic uveal melanoma no
standard systemic agent currently exists. Several
studies have reported response rates of less than 10%
TABLE 3. Toxicity according to National Cancer Institute Common Toxicity Criteria version 2.0 (n = 18)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Leukocyte nadir 63.2% (12) 10.5% (2) 5.3% (1) 5.3% (1) 10.5% (2)
Bilirubin 23.3% (5) 21.1% (4) 36.8% (7) 0% (0) 10.5% (2)
Alkaline phosphatase 5.3% (1) 42.1% (8) 21.1% (4) 26.3% (5) 0% (0)
ALAT 15.8% (3) 26.3% (5) 26.3% (5) 21.1% (4) 5.3% (1)
ASAT 5.3% (1) 42.1% (8) 21.1% (4) 21.1% (4) 5.3% (2)
Aspartate transaminase, ASAT; Alanine transaminase, ALAT
TABLE 4. Treatment results of IHP with 200 mg melphalan in patients with isolated liver metastases of primary tumors other
than uveal melanoma
Patient Primary tumor
Hepatic
response
Location
progression
Time to progression
(months)
Overall survival
after IHP (months)
Survival after diagnosis
of liver metastases
(months)
1 Neuroendocrine tumor Stable disease Extrahepatic 5.9 8.9 18
2 Neuroendocrine tumor (carcinoid)Partial remission Extrahepatic 33.4 89.4
a 95.3
a
3 GIST Stable disease Extrahepatic 8 36.2 36.9
4 GIST Stable disease Hepatic 13 22 23.8
5 HCC Partial remission Hepatic 5.9 14.4 26.8
6 High-grade sarcoma Complete remissionBoth 27.1 50.2 52
a Patient was still alive at the end of follow-up. Data is censored at the end of follow-up.
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FIG. 1. Overall and progression-free survival curves for uveal
melanoma patients. Of the 13 uveal melanoma patients, 12 patients
were treated with IHP and included in the progression-free and
overall survival analysis.
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29,30 Results
with immunotherapy, as for example interferon-a and
interleukin-2, are equally disappointing with no or
only minor responses.
31,32 Peters et al. reported the
use of HAI with fotemustine, an alkylating agent, in
101 uveal melanoma patients with liver metastases.
33
Fotemustine was infused in the hepatic artery for a 4-
week induction period followed by a maintenance
treatment every 3 weeks until disease progression. A
median of eight infusions per patient were delivered.
Catheter related complications occurred in 23% of
patients. The overall response rate was 36%, with
median overall survival of 15 months and 2-year
survival rate of 29%. Although the response rate of
fotemustine infusion is similar to our results with IHP
in uveal melanoma patients, the overall survival of
15 months seems superior to our observed
10 months. The difference could be explained by a
difference in hepatic tumor load, but numbers esti-
mating the tumor burden are not reported. The im-
proved survival could also be attributed to the
combination with debulking surgery in 38 patients
undergoing HAI with fotemustine.
Alexander et al. reported the results of IHP with
1.5 mg/kg melphalan in 29 uveal melanoma patients.
Hepatic response rate was 62% with progression-free
survival of 8 months and overall survival of
12.1 months. In our patients the response rate
was less, only 33%, but 50% of patients did show
stable disease with median time to progression of
6.6 months and overall survival of 10 months, similar
to the results of Alexander et al. Although these re-
sults may seem disappointing as compared to IHP
in other primary tumors, there is a survival beneﬁt
compared to a median survival of 2 months in uveal
melanoma patients with liver metastases without
antitumor treatment.
34 Moreover, currently we have
no accepted alternative treatment options for uveal
melanoma patients with unresectable isolated liver
metastases.
Treatment of neuroendocrine liver metastases is
aimed at improvement of the hormonal symptoms
through reduction of tumor burden. Results of
systemically administered agents have been disap-
pointing in neuroendocrine cancer metastases with
response rates around 6–40% for cytostatic
drugs and 11% for interferon-a.
35–38 Symptomatic
improvement can be achieved in up to 70% of
patients with somatostatin analogs such as octreo-
tide, but objective tumor response occurs in less
than 10% and drug resistance can develop in
3–12 months.
39–42 Recently attention has shifted to
the development of radiolabeled somatostatin
analogs. Valkema et al. reported the response after
peptide receptor radionuclide therapy with [90Y-
DOTA0, Tyr3] octreotide in 56 patients with
advanced neuroendocrine tumors.
43 Overall, 58% of
patients experienced improvement of symptoms, the
median progression free survival was 29 months with
a median overall survival of nearly 37 months. Several
studies have been reported on the use of RFA for
neuroendocrine liver metastases.
44–46 In the largest
published study the laparoscopic ablation of 234
hepatic lesions in 34 patients is reported.
47 Symptoms
were relieved in 95% of the patients, with signiﬁcant
or complete symptom control in 80% of them for a
mean duration of 10 months. New liver metastases
developed in 28% of these patients, new extrahepatic
disease in 25%, and local liver recurrence in 13%, at a
mean follow-up of 1.6 years. Grover et al. reported an
overall response rate of 50% with IHP in 13 neuro-
endocrine tumors with a median progression free
survival of 7 months.
48 Although we treated only
two patients with neuroendocrine tumors, one
patient with a carcinoid showed a partial response for
33.4 months. In neuroendocrine carcinoid tumors
caution should be taken to block hormone secretion,
because systemic complications have been reported
during RFA of carcinoids.
49
Imatinib has become the standard ﬁrst-line
systemic treatment for advanced GIST. GISTs have
characteristic gain-of-function mutations in the KIT
oncogene that results in overexpression of the
KIT-protein (CD117).
50 Imatinib is a potent, speciﬁc
KIT/PDGFR-small molecule tyrosine kinase inhibi-
tor with a patient beneﬁt rate (prolonged stable dis-
ease and response) of up to 90% and median
progression-free survival of 2.5–3 years.
51,52 Second-
line treatment with sunitinib, an oral multitargeted
receptor tyrosine kinase inhibitor, can add a median
of 8 months in about 60% of patients.
53 Before the
imatinib/sunitinib era no systemic treatment options
existed for metastatic GIST. Hepatic arterial
chemoembolization was one of the options for
patients with hepatic metastasis derived from GIST
resulting in a mean survival of 9.5–11.4 months.
54,55
The addition of RFA to transcatheter arterial
chemoembolization could increase survival to up to
25 months.
56 To our knowledge there have been no
reports published on IHP for GIST. In our study two
patients with GIST were included and showed stable
disease with disease-free survival of 8 and 13 months,
respectively, and overall survival of 36.2 and
22 months, respectively. Both patients were treated
prior to the imatinib/sunitinib era. The aforemen-
tioned local treatment options, including IHP, can
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and sunitinib with progressive liver lesions without
further extrahepatic progression.
In recent studies with IHP, melphalan with or
without TNF-a, has been the only chemotherapeutic
agent used. Melphalan is an alkylating agent that is
mainly used in the systemic treatment for multiple
myeloma, isolated limb, lung, and liver perfusion.
Little is known about the eﬀectiveness of systemic
melphalan treatment in the tumors described above.
If IHP is considered as serious treatment option for
patients with a variety of primary tumors other
tumor-speciﬁc agents need to be studied to improve
tumor response. Ideally, tumor-speciﬁc IHP agents
should be developed. A wide range of agents is pos-
sible because, for example, IHP oﬀers the additional
advantage that, as long as agents are speciﬁc to the
tissue of origin of the primary tumor, they do not
have to diﬀerentiate between malignant and healthy
tissue due to the local exposure in the liver.
In conclusion, IHP appears to be feasible in
patients with liver metastases from a variety of
primary tumors. To improve responses in IHP, the
role of new agents tailored to speciﬁc tumor types
needs to be assessed.
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